GHK-Cu and AHK-Cu are copper(II) complexes of two tripeptides that differ at a single position: GHK begins with glycine, AHK with alanine. Both keep histidine at position 2 and lysine at position 3, so both present the same three-nitrogen site that binds copper. The real differences are not chemical subtlety but provenance and evidence: GHK was isolated from human plasma in 1973 and its copper complex has been characterized by crystallography, spectroscopy and calorimetry, while AHK is a synthetic analog whose best-known study is a 2007 report in cultured human dermal papilla cells and isolated hair follicles.
This comparison sets out the identifiers for both compounds, what one extra methyl group does and does not change, where each sequence came from, how deep the published record goes on each, and what to check on a certificate when the two arrive in the same shipment.
Side by side
Values for the free peptides are from PubChem. GHK's copper complex has its own records; AHK's does not have an equally well-defined one, which is itself a finding.
| GHK / GHK-Cu | AHK / AHK-Cu | |
|---|---|---|
| Sequence | Gly-His-Lys | Ala-His-Lys |
| One-letter | GHK | AHK |
| Residue 1 | Glycine (no side chain) | L-alanine (methyl side chain) |
| Free peptide formula | C14H24N6O4 | C15H26N6O4 |
| Free peptide mass | 340.38 g/mol | 354.41 g/mol |
| Free peptide CAS | 49557-75-7 | 126828-32-8 |
| Free peptide PubChem CID | 73587 | 7408502 |
| Copper complex CAS | 89030-95-5 (prezatide copper) | No equivalent record verified |
| Copper complex PubChem CID | 71587328 (1:1), 9831891 (2:1) | No equivalent record verified |
| INCI name | Copper Tripeptide-1 (CosIng) | No CosIng entry found by name or CAS |
| Origin | Isolated from human plasma, 1973 | Synthetic analog |
| Structural characterization of the Cu complex | X-ray and solution structures published | Not found in the primary literature |
| Measured Cu(II) affinity | Conditional Kd 7.0 × 10⁻¹⁴ M at pH 7.4 | Not found in the primary literature |
Two entries in that table are worth reading twice. AHK-Cu is widely sold and widely discussed, but searches of the European Commission's CosIng inventory in September 2026, by name and by the CAS number of the free peptide, returned no matching ingredient entry. An ingredient list that names "copper tripeptide-1" is therefore referring to GHK-Cu. And while the copper coordination of AHK is easy to predict from its sequence, that prediction has not been pinned down by a published structure in the way GHK's has.
What one methyl group changes
The difference between glycine and L-alanine is a single methyl group on the alpha carbon. Three consequences follow.
Chirality. Glycine is the only achiral proteinogenic amino acid. Replacing it with L-alanine introduces a stereocenter at residue 1, which means AHK has a D-alanine counterpart that GHK cannot have. For a supplier, that adds a possible stereochemical impurity; for an analyst, it means chiral or diastereomer-resolving methods can matter in a way they do not for GHK.
Backbone flexibility. Glycine's lack of a side chain makes it the most conformationally free residue in peptides, sampling backbone angles that other residues cannot. Adding a methyl group restricts that freedom. In a tripeptide whose copper site is formed by the N-terminal amine and the first backbone amide, a modest change in the conformational space near residue 1 is the most plausible place for the two complexes to differ.
Hydrophobicity and mass. The methyl group raises the molecular weight by 14 g/mol and makes the molecule marginally less polar. On a reversed-phase HPLC column, AHK typically elutes slightly later than GHK under the same conditions, which is a practical way to tell them apart in a mixed sample.
What the methyl group does not change is the copper-binding motif. Both peptides carry histidine at position 2, the arrangement usually written Xaa-His. In GHK, the copper ion is held in the equatorial plane by three nitrogen atoms: the N-terminal amine, the deprotonated amide nitrogen of the bond between residues 1 and 2, and a nitrogen of the histidine imidazole, with the fourth position labile and open to water or another ligand. Those three donors are all present in AHK as well, so the same coordination is expected. Expected is the correct word: the structural work published by Hureau and colleagues was done on GHK and on the albumin-derived DAHK peptide, not on AHK.
The lysine in both peptides is not part of the metal site. Its side-chain amine stays protonated and free at neutral pH, which is why both complexes carry a positive charge overall and why lysine is the residue that dominates the peptides' solubility and their behavior on ion-exchange media.
Where each sequence came from
GHK was found, not designed. Loren Pickart and Martin Thaler reported it in 1973 as a tripeptide in human serum that changed the behavior of liver cells in culture, and a 1980 paper from the same authors showed that it circulates complexed with copper and iron and binds several transition metals at physiological pH while ignoring calcium, potassium and sodium. Later reviews by Pickart and colleagues collect the cell and animal work that followed, and a 2020 crystallography paper put the same binding site to an entirely different use, fusing GHK to test proteins as a copper-based phasing tag. The full background is in the profile of GHK-Cu.
AHK is an analog. It appears in the literature mainly through a 2007 study by Pyo and colleagues, who tested L-alanyl-L-histidyl-L-lysine-Cu²⁺ at 10⁻¹² to 10⁻⁹ M in two systems: cultured human dermal papilla cells, a specialized fibroblast population, and human hair follicles in ex-vivo organ culture. The measured endpoints were follicle elongation, cell proliferation, apoptosis by annexin V and propidium iodide labeling with flow cytometry, the Bcl-2 to Bax ratio, and cleaved caspase-3 and PARP. Whatever one makes of the conclusions, the useful point for a laboratory is the concentration range and the assay panel: picomolar to nanomolar, in a fibroblast lineage, read out by proliferation and apoptosis markers.
The contrast in depth is the honest summary of this comparison. GHK-Cu has decades of chemistry and biology behind it, from several groups. AHK-Cu has a much thinner record, and much of what circulates about it online extrapolates from GHK data or from ingredient marketing rather than from studies on AHK itself.
Which is which in the vial
Both compounds arrive as lyophilized powders, and both are blue to violet when complexed with copper, so the powders look alike. Distinguishing them and confirming either one comes down to the certificate of analysis, which the post on how to read a peptide certificate of analysis covers line by line. Three checks matter here.
- Mass. The 14 Da difference between the free peptides, 340.4 versus 354.4, is unambiguous by mass spectrometry. With copper bound, both show the characteristic two-isotope copper pattern (⁶³Cu and ⁶⁵Cu, roughly 69 and 31 percent), which is a quick way to confirm that the metal is actually present rather than lost during workup.
- Salt form and copper content. Both are often supplied as acetate salts, and the counter-ion changes the formula weight used to convert net content into a molar concentration. Where a certificate reports copper content or a peptide-to-copper ratio, check it against the 1:1 complex.
- Chromatographic identity. On reversed-phase HPLC, purity is expressed as the area of the principal peak against the total signal. Because AHK is slightly more hydrophobic, a co-injection of the two is the simplest confirmation that a sample is the compound named on the label.
Using them in parallel
Because the two differ by one methyl group and share a binding motif, they make a natural pair in an experiment. A few design notes follow from the chemistry rather than from any claimed effect.
- Run the right controls. Free peptide without copper, and a simple copper salt at matched concentration, separate a copper-delivery effect from a peptide effect. Both compounds can hand copper to competing ligands, so this control is not optional.
- Mind the buffer. Strong chelators such as EDTA, high concentrations of free histidine, and strong reducing agents all compete for or reduce the copper. Keep the buffer composition identical across arms.
- Match the concentration range. The published AHK work sits at picomolar to nanomolar concentrations; much of the GHK cell literature is in the nanomolar range as well. Starting several orders of magnitude higher is a common way to end up studying copper toxicity instead of the peptide.
- Prepare fresh. Both complexes are best dissolved in water or a simple buffer, aliquoted for single use and kept frozen, with solutions protected from light.
Anhydrolabs supplies GHK-Cu and AHK-Cu as lyophilized powders in vacuum-sealed vials, and as 10-vial kits. Multi-peptide blends of short peptides are covered separately in the post on the KLOW blend. For another peptide whose cosmetic-ingredient name differs from the name used in research supply, see the profile of Snap-8.


